Learn more about Peter Attia’s digital program
Where a study on metformin and cardiovascular disease fell short – and what it can teach us
An investigation on metformin, diabetes, lipid biology, and cardiovascular disease offered little insight on any of these topics, but it illustrates common problems in scientific research
#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.
“What we try to do is quite simple. We try to find drugs that will slow aging and extend mouse lifespan.” —Rich Miller
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
#270 ‒ Journal club with Andrew Huberman: metformin as a geroprotective drug, the power of belief, and how to read scientific papers
“This paper basically addresses how our beliefs about the drugs we take impacts how they affect us at a real level, not just at a subjective level, but at a biological level.” —Andrew Huberman
More than glycemic control: SGLT2 inhibitors may extend lung cancer survival
A retrospective study offers hope
#246 – AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent
“The thing that concerns me the most with these drugs. . .is this drive towards sarcopenia.” —Peter Attia
A recent metformin study casts doubts on longevity indications
A new retrospective study contradicts previous evidence of metformin’s potential effects on lifespan extension in a general population, but for real answers, randomized trials are needed.
The difference between a ‘clean’ drug and a ‘dirty’ drug
This clip is from episode #207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin, originally released on May…
#207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin
“It’s really hard to know, in my view, how important sirtuins are as longevity factors…If we accept that, then it’s difficult to know [the importance of] activation of sirtuins by NAD as a longevity mechanism.” —Matt Kaeberlein
About TAME: A Metformin Anti-Aging Clinical Trial with Nir Barzilai, M.D.
This video clip is from episode #204 – Centenarians, metformin, and longevity with Nir Barzilai, M.D., originally released on April…